Peptide IP Protection: Patents, Trade Secrets and Lab Records

Peptide intellectual property in the United States rests on four federal tools: patents, trade secrets, copyrights and trademarks. For peptide work, patents and trade secrets do most of the work. A patent can cover a sequence, a composition, a synthesis method or a method of use, if it meets statutory tests. A trade secret covers confidential know-how, but only while the owner takes reasonable steps to keep it secret. Both depend on documentation: a team that can show exactly what it made, how it made it and who had access is in a stronger position than one that cannot. This is why we treat batch-level records, including Certificates of Analysis (COAs), as part of a laboratory’s IP file and not only as a quality control item.

This article is general information for research teams, not legal advice. Questions about a specific invention belong with a registered patent attorney or agent, or with your institution’s technology transfer office. For Research Use Only. Not for human or veterinary use.

TL;DR

• Patents, trade secrets, copyrights and trademarks are the four federal categories. Peptide programs mostly rely on patents and trade secrets (Congressional Research Service).
• A peptide claim must fall within a statutory category, avoid being a bare natural phenomenon, and be useful, novel, non-obvious and clearly described (USPTO).
• Amgen v. Sanofi reaffirmed full-scope enablement; the USPTO’s subsequent guidance continues to apply the Wands factors.
• Federally funded inventions carry Bayh-Dole obligations, and trade secrets require documented reasonable measures.
• Lot-specific COAs and sequence characterization data give your lab a verifiable record of the material behind every result.

Table of Contents

• What IP protection means for peptide research
• What peptide subject matter can be patented
• Enablement after Amgen v. Sanofi
• The sequence listing rule
• Trade secrets and confidentiality in peptide work
• Federally funded research and Bayh-Dole
• Research use of patented compounds
• Checking existing patents before you build
• Documentation that supports your IP position
• Sourcing with the paper trail in mind
• Our perspective
• FAQ
• Sources

What IP protection means for peptide research

The Congressional Research Service describes federal intellectual property as patents, copyrights, trademarks and trade secrets. Each protects something different, and a peptide program usually touches more than one.

• Patents protect new and useful processes, machines, manufactures and compositions of matter. For peptides, that can mean a novel sequence, a modified analog, a formulation or a manufacturing method.
• Trade secrets protect commercially valuable confidential information, such as an internal purification procedure or an assay design that is not published.
• Trademarks protect names and marks that identify a product or a source.
• Copyrights protect original expression, such as written protocols and software, not the underlying scientific idea.

Timing matters. According to the same CRS summary, most patents issued today expire 20 years from the application filing date, though the term can be extended in certain situations such as prosecution delays. During that period, anyone else who wants to practice the invention generally needs the holder’s permission. A trade secret has no fixed term. It lasts as long as the secrecy and the commercial value last.

What peptide subject matter can be patented

The USPTO’s life science presentation lists several patent opportunities for biologics: nucleotide and amino acid or polypeptide sequences, vectors, modified organisms, manufacturing methods, formulations and methods of use. A research team developing a new sequence therefore has more than one angle to consider. A claim might target the molecule itself, the way it is made, a stable preparation, or a defined research method that uses it.

The four conditions

The USPTO states that a utility patent may cover any new and useful process, machine, manufacture or composition of matter, and that four conditions must be met: the invention must work, be clearly described, be novel and be non-obvious. In plain terms:

1. It works. You can show real utility. The USPTO’s examination manual requires a utility that is specific, substantial and credible, and a rejection is appropriate when no specific and substantial utility is identified or the asserted utility is not credible.
2. It is clearly described. The specification must teach others how to make and use what is claimed.
3. It is novel. The same thing has not already been disclosed.
4. It is non-obvious. The invention is not a predictable variation of what is already known.

The natural-phenomenon problem

The same manual explains that a claim must fall within one of the four statutory categories of 35 U.S.C. § 101 and must not be directed to a judicial exception, meaning an abstract idea, a law of nature or a natural phenomenon, unless the claim includes significantly more than the exception. The manual cites Alice Corp. v. CLS Bank (2014) and the Myriad Genetics decision (2013) in this context. For peptide researchers, the practical lesson is that a sequence identical to one found in nature is a difficult claim, while a modified, engineered or specifically formulated molecule, or a defined process for making it, is built on firmer ground. Your patent counsel decides how that applies to your sequence.

Enablement after Amgen v. Sanofi

On May 18, 2023, the Supreme Court decided Amgen Inc. v. Sanofi, 598 U.S. 594, unanimously holding that Amgen’s patents on a genus of antibodies were invalid for lack of enablement under 35 U.S.C. § 112(a), and reaffirming that the more a patent claims, the more its specification must enable. On January 10, 2024, the USPTO followed with guidelines in the Federal Register (89 FR 1563) directing examiners to apply the existing In re Wands factors, particularly for claims that functionally define a broad genus in unpredictable fields.

The decision concerned antibodies, but the logic reaches any class of molecules where claims are written around a function instead of a defined structure. For a peptide lab, it supports a simple habit: claim what you can actually make and describe. Drafting around a single defined sequence, or a narrow, well-characterized family of sequences, with working examples, is more defensible than claiming every molecule that produces a given result. That is also where experimental records become evidence. Analytical data showing that each example was synthesized, purified and identified as described makes the specification stronger.

The sequence listing rule

Sequence disclosures have a formal requirement. A USPTO final rule effective July 1, 2022 requires applications filed on or after that date that disclose nucleotide or amino acid sequences to submit a Sequence Listing XML in accordance with WIPO Standard ST.26, ending paper and PDF sequence listings. The same rule removed the option to include sequences with fewer than 4 specifically defined amino acids, and replaced the numeric identifiers of the earlier ST.25 standard with INSDC data elements.

Two practical points follow for peptide teams:

• Keep the exact sequence, including any modifications, in a controlled, machine-readable form from the start of the project. Reconstructing it from lab notebooks at filing time invites errors.
• Very short peptides fall below the 4-residue threshold for the XML listing, so confirm with counsel how your shortest sequences are to be presented.

If your team needs a refresher on how sequence identity is established in the lab, our guides on peptide sequence characterization methods and amino acid sequencing basics cover the analytical side.

Trade secrets and confidentiality in peptide work

Not every advantage should be patented. A patent requires publication of the invention, while a trade secret stays private. Under the Defend Trade Secrets Act of 2016 (18 U.S.C. § 1839(3)), a trade secret includes scientific, technical and engineering information such as formulas, methods and processes, provided the owner has taken reasonable measures to keep it secret and it derives independent economic value from not being generally known. Federal law added a general civil remedy in 2016, after federal criminal remedies in 1996, and reasonable measures include restricting access, requiring confidentiality agreements and using secure computer systems.

A Berkeley Center for Law presentation for early-stage life science companies recommends confidentiality obligations, IT and physical security, and restricted access. In a peptide lab, that translates into concrete steps:

• Non-disclosure agreements before sharing sequences, synthesis routes or unpublished assay data with collaborators or vendors.
• Access limits on freezer inventories, electronic notebooks and sequence databases.
• A written record of who received which material and under what terms.
• Clear labeling of confidential documents.

One limit is worth knowing. CRS notes that misappropriation involves improper means such as theft or breach of a nondisclosure agreement, while acquiring a secret through reverse engineering or independent discovery is not misappropriation. Public disclosure can defeat secrecy, while patent rights, contracts and other restrictions may still apply; so a trade secret is better suited to process know-how than to a sequence you plan to distribute. Teams that follow a written research-use-only policy for how materials are received, labeled and handled also tend to have cleaner custody records.

Federally funded research and Bayh-Dole

Federally funded teams have additional obligations. NIH’s inventions and patents policy explains that retaining rights and title to subject inventions requires compliance with Bayh-Dole and implementing regulations. This is not an automatic transfer of unrestricted ownership: disclosure, election, filing, government rights and award-specific duties must be reviewed with the institution’s technology transfer office.

For NIH awards, NIH notice NOT-OD-18-233 states that, effective October 1, 2018, the final Bayh-Dole regulations apply to all new and continuation awards, and funding recipients must obtain written assignments from researchers of the entire right, title and interest in each subject invention made under an award. If you work under a federal grant, report a new peptide invention to your technology transfer office before you publish or present it. Disclosure timing can affect patent rights, and the office will know the reporting deadlines in your award terms.

Research use of patented compounds

Researchers often ask whether working with a patented compound is permitted. The answer is narrow and fact-specific, and it should not be treated as a general exemption. In Merck KGaA v. Integra Lifesciences I, Ltd. (545 U.S. 193, 2005), the Supreme Court held that use of patented compounds in preclinical studies is protected under 35 U.S.C. § 271(e)(1) as long as there is a reasonable basis to believe the experiments will produce information relevant to an FDA submission. The case involved RGD peptides used in preclinical research at Scripps Research Institute, as summarized in a Cold Spring Harbor Perspectives in Medicine review.

The provision is tied to information relevant to a regulatory submission, so it does not cover every experiment. A project outside that scope should be reviewed by counsel before work begins. The same caution applies to the label “research use only”: it describes intended use and is not a blanket legal exemption. Our overview of U.S. research peptide regulations and FDA warnings covers that regulatory side in neutral terms.

Checking existing patents before you build

Before investing in a sequence, a team should know what already exists. A reasonable process looks like this:

1. Define the claim elements of your own work. Write down the exact sequence, modifications, synthesis method and intended research use.
2. Search patent and published-application databases. Use sequence searches as well as keyword and inventor searches, since the same peptide appears under several names, abbreviations and CAS records.
3. Read the claims, not the abstract. Scope is set by the numbered claims at the end of each patent. Note the filing date, the status and whether a term extension or a terminal disclaimer applies.
4. Look at prior art in the literature. Published papers and earlier applications can limit patentability. Public disclosure does not by itself establish freedom to operate or extinguish other patent rights.
5. Ask a patent attorney for a freedom-to-operate opinion when a commercial path is realistic. Reading claims is a legal skill, and a search by itself does not establish that a project is clear.

Consistent naming makes the search much easier. Recording each compound by sequence, CAS number and supplier lot lets you tie a search result to the material on your bench. The same identifiers drive customs classification, which we cover in our guide on current research resources.

Documentation that supports your IP position

Patent claims and trade secrets both depend on proof. A court or examiner will ask what was made, when, by what method, and whether it was what you say it was. For peptide work, the following records are worth keeping for every project:

Preserve the connection between each experimental result and its material record. A supplier-documentation check supports traceability, but a COA cannot establish inventorship, ownership, patentability or freedom to operate.

The USPTO also notes that patents can serve as collateral for a bank loan or be sold, and that exclusivity affects how products reach the market. A diligence reviewer examining a peptide asset will look at exactly the records listed above.

Questions to settle before you publish or share

• Has a patent application been filed, or has your technology transfer office cleared the disclosure?
• Are collaborators and vendors bound by written confidentiality terms?
• Does the paper or poster reveal a synthesis route you intended to keep as a trade secret?
• Do you hold the lot records for every batch used in the reported experiments?

Sourcing with the paper trail in mind

Vertex Labs supplies research-use-only materials. Review the selected product presentation and its available batch-specific COA; documentation availability and reported results vary by lot. A published purity standard does not replace the findings of an individual laboratory report. Materials are offered for lawful research to eligible purchasers aged 21 and over in the United States and Puerto Rico. Custom synthesis and bulk procurement are available upon request, with scope and documentation confirmed for the individual order.

The point for IP is traceability. When a result is tied to a batch with its own COA, your notebook entry, your sequence file and your supplier record all refer to the same material. You can review the research peptide catalog or the full shop to see the product lines, or start from the Vertex Labs homepage for custom synthesis and bulk procurement inquiries.

For Research Use Only. Not for human or veterinary use.

Our perspective

Intellectual property in peptide research is decided largely by records. A claim can be well drafted and still weak if the team cannot show what molecule it made, which batch it used and how that material was handled.

Batch documentation can support a research record, but it is only one part of that record. Preserve experimental procedures, identity evidence and ownership agreements separately; do not treat a supplier’s document as a legal opinion or a guarantee of IP protection.

We also think research teams are better served by suppliers who describe their products plainly as research-use-only and who support documented purchases. That clarity helps a lab keep its own policies, its regulatory position and its IP file consistent.

For Research Use Only. Not for human or veterinary use.

Vertex Labs Editorial Team

FAQ

Can a peptide sequence be patented in the United States?

A sequence can be a patent opportunity, but it must meet the statutory tests. The USPTO requires that the invention be new, useful, non-obvious and clearly described, and a claim directed to a natural phenomenon must include significantly more than that phenomenon. A patent attorney can assess a specific sequence.

Is a trade secret better than a patent for a synthesis method?

It depends on whether the method can be kept confidential and whether competitors could find it independently. A trade secret needs reasonable protective measures and has no fixed term, while a patent requires public disclosure and lasts roughly 20 years from filing. Reverse engineering and independent discovery are lawful ways to obtain a secret.

Does the research use label give legal protection against patent claims?

No. The label describes the intended use of a product and is not a legal exemption. Patent law has narrow provisions, such as the safe harbor interpreted in Merck v. Integra, and they depend on the facts of the research. Consult counsel for any project involving patented compounds.

What records should a lab keep to support a peptide patent filing?

Keep the exact sequence and modification list, synthesis and purification notes, lot-specific COAs, identity data, storage logs and records of who received material. Federally funded teams should also keep invention disclosure records for the technology transfer office.

Checking Vertex batch evidence

Open the current catalog and COA directory, then match the selected presentation and vial lot to the complete laboratory report. For example, the MOTS-C product page lists separate reports for its 20 mg and 40 mg presentations. A report for one presentation does not verify another or establish which lot is currently shipping. Purity results do not establish sterility, counterion composition, accreditation or clinical suitability unless those matters are separately documented.

For lawful laboratory research only. Purchasers must meet Vertex’s eligibility requirements, including age 21 or older. Sales are directed to the United States and Puerto Rico. Not for human or veterinary use.

Sources

• Intellectual Property Law: A Brief Introduction, Congressional Research Service
• Patent essentials, USPTO
• MPEP 2104, Requirements of 35 U.S.C. 101, USPTO
• Life Science Patents in Practice, USPTO
• Amgen v. Sanofi (2023): The Enablement Ruling
• Federal Register, Volume 87, Issue 98, May 20, 2022
• Early-Stage Life Science Companies: Key IP and Trade Secret Issues, Berkeley Center for Law
• NOT-OD-18-233: Notice Regarding 2018 Bayh-Dole Act Final Regulations, NIH
• An Inventor’s Guide, 2026
• Merck KGaA v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005)
• Research Use Exemptions to Patent Infringement for Drug Discovery

Recommended

• Research Peptide Rules for U.S. Labs: FDA Warnings Expose RUO Risk
• Maintaining Peptide Compliance in a Regulated Lab
• Regulated Peptide Handling Best Practices for Labs
• Peptide Documentation Standards for Academic Labs